Black Rock Inc. Impel Pharmaceuticals Inc Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.31 - $1.75 $1,594 - $8,998	5,142 Added 29.39%	22,635 $9,000
Q2 2023 Aug 11, 2023	SELL	$1.08 - $2.75 $582 - $1,482	-539 Reduced 2.99%	17,493 $22,000
Q1 2023 May 12, 2023	BUY	$0.96 - $4.1 $443 - $1,894	462 Added 2.63%	18,032 $25,000
Q4 2022 Feb 13, 2023	SELL	$2.59 - $4.0 $232,281 - $358,736	-89,684 Reduced 83.62%	17,570 $65,000
Q3 2022 Nov 14, 2022	BUY	$5.78 - $9.32 $56,545 - $91,177	9,783 Added 10.04%	107,254 $523,000
Q2 2022 Aug 12, 2022	SELL	$5.83 - $10.12 $1.45 Million - $2.51 Million	-248,201 Reduced 71.8%	97,471 $908,000
Q1 2022 May 12, 2022	SELL	$5.86 - $9.85 $55,113 - $92,639	-9,405 Reduced 2.65%	345,672 $2.2 Million
Q4 2021 Feb 10, 2022	BUY	$8.33 - $12.14 $719,270 - $1.05 Million	86,347 Added 32.13%	355,077 $3.06 Million
Q3 2021 Nov 09, 2021	BUY	$8.38 - $26.13 $148,049 - $461,638	17,667 Added 7.04%	268,730 $3.27 Million
Q2 2021 Aug 11, 2021	BUY	$7.33 - $15.2 $1.84 Million - $3.82 Million	251,063 New	251,063 $2.22 Million

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.